E. Estey

发表

Treatment of newly‐diagnosed acute myelogenous leukaemia in patients aged 80 years and above

E. Estey, S. Pierce, S. Pierce, 1996, British journal of haematology.

Chemotherapy versus transplants for acute myelogenous leukemia in second remission.

J. Klein, M. Oken, R. Gray, 1996, Leukemia.

H. Tilly, B. Quesnel, E. Archimbaud, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid

John Calvin Reed, M. Konopleva, Z. Estrov, 1999, Leukemia.

Treatment of relapsed and refractory acute myelogenous leukemia

E. Estey, 2000, Leukemia.

Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy

J. Seymour, L. Campbell, E. Estey, 1999, Leukemia.

New drugs for therapy of AML

E. Estey, 2002, Leukemia.

A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia.

H. Kantarjian, S. Pierce, S. Kornblau, 1996, Blood.

AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.

H. Kantarjian, A. Cork, E. Freireich, 1992, Hematologic pathology.

Pre-and post-transplant quanti fi cation of measurable ( ‘ minimal ’ ) residual disease via multiparameter fl ow cytometry in adult acute myeloid leukemia

F. Appelbaum, M. Othus, M. Mielcarek, 2016 .

Routine bone marrow exam during first remission of acute myeloid leukemia.

S. Pierce, E. Estey, 1996, Blood.

Acute myeloid leukemia-type chemotherapy for myelodysplasia.

H. Kantarjian, P. Anderlini, S. Pierce, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?

J. Byrd, E. Estey, R. Howard, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of myelodysplastic syndromes with AML-type chemotherapy

M. Andreeff, H. Kantarjian, S. Pierce, 1993 .

High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).

M. Andreeff, H. Kantarjian, S. Kornblau, 1995, Cytokines and molecular therapy.

Long‐term follow‐up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M. D. Anderson Cancer Center

S. Strom, E. Freireich, M. Keating, 1997, Cancer.

Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.

P. Thall, E. Estey, H. Kantarjian, 1992, Blood.

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)

I. Bernstein, F. Appelbaum, M. Loken, 2002, Leukemia.

method: potential for predicting relapse promyelocytic leukemia by the fluorescence in situ hybridization Detection of residual leukemic cells in patients with acute

A. Deisseroth, K. Chang, E. Estey, 2013 .

Detection of residual leukemic cells in patients with acute promyelocytic leukemia by the fluorescence in situ hybridization method: potential for predicting relapse.

A. Deisseroth, K. Chang, L. Zhao, 1995, Blood.

Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia

M. Konopleva, M. Andreeff, J. Sebolt-Leopold, 2005, Leukemia.

Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.

P. Thall, E. Estey, H. Kantarjian, 1997, Blood.

Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine.

P. Thall, E. Estey, H. Kantarjian, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, Leukemia.

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

P. Thall, M. Andreeff, H. Kantarjian, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia.

S. Stass, M. Keating, S. Pierce, 1995, Leukemia.

Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha.

E. Estey, Z. Estrov, M. Talpaz, 1994, Leukemia.

Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy

H. Kantarjian, M. Keating, S. Pierce, 1999, Leukemia.

Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia

P. Thall, H. Kantarjian, S. Kornblau, 1997, Leukemia.

Comparison of acute myeloid leukemia patients at MD Anderson: 1982–1986 vs 1992–1996

P. Hoff, S. Pierce, E. Estey, 1997, Leukemia.

The prognostic significance of auer rods in myelodysplasia

E. Estey, J. Seymour, 1993, British journal of haematology.

Prognostic value of residual normal metaphases in acute myelogenous leukemia patients presenting with abnormal karyotype.

S. Pierce, H. Ghaddar, E. Estey, 1995, Leukemia.

leukemia (letter) patients with relapsed or primary refractory acute myelogenous A stratification system for evaluating and selecting therapies in

H. Kantarjian, S. Kornblau, M. Keating, 2011 .

Prognostic factors in acute myelogenous leukemia

E. Estey, 2001, Leukemia.